Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt No Debt
ECYT's Cash to Debt is ranked higher than
78% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. ECYT: No Debt )
ECYT' s 10-Year Cash to Debt Range
Min: 0.69   Max: No Debt
Current: No Debt

Equity to Asset 0.95
ECYT's Equity to Asset is ranked higher than
97% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ECYT: 0.95 )
ECYT' s 10-Year Equity to Asset Range
Min: 0.45   Max: 0.95
Current: 0.95

0.45
0.95
F-Score: 5
Z-Score: 15.44
M-Score: -1.02
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 11.70
ECYT's Operating margin (%) is ranked higher than
89% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ECYT: 11.70 )
ECYT' s 10-Year Operating margin (%) Range
Min: -20228.8   Max: -28.27
Current: 11.7

-20228.8
-28.27
Net-margin (%) 12.14
ECYT's Net-margin (%) is ranked higher than
89% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. ECYT: 12.14 )
ECYT' s 10-Year Net-margin (%) Range
Min: -21220.94   Max: -27.8
Current: 12.14

-21220.94
-27.8
ROE (%) 7.70
ECYT's ROE (%) is ranked higher than
91% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. ECYT: 7.70 )
ECYT' s 10-Year ROE (%) Range
Min: -492.46   Max: -16.24
Current: 7.7

-492.46
-16.24
ROA (%) 5.68
ECYT's ROA (%) is ranked higher than
91% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. ECYT: 5.68 )
ECYT' s 10-Year ROA (%) Range
Min: -86.45   Max: -9.57
Current: 5.68

-86.45
-9.57
ROC (Joel Greenblatt) (%) 263.59
ECYT's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. ECYT: 263.59 )
ECYT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -3920.55   Max: -523.61
Current: 263.59

-3920.55
-523.61
EBITDA Growth (3Y)(%) -72.10
ECYT's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. ECYT: -72.10 )
ECYT' s 10-Year EBITDA Growth (3Y)(%) Range
Min: 0   Max: -70.2
Current: -72.1

EPS Growth (3Y)(%) -71.60
ECYT's EPS Growth (3Y)(%) is ranked higher than
52% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. ECYT: -71.60 )
ECYT' s 10-Year EPS Growth (3Y)(%) Range
Min: 0   Max: -70.5
Current: -71.6

» ECYT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

ECYT Guru Trades in Q4 2013

Paul Tudor Jones 16,744 sh (New)
RS Investment Management 510,400 sh (+6.27%)
Jim Simons Sold Out
» More
Q1 2014

ECYT Guru Trades in Q1 2014

Steven Cohen 23,228 sh (New)
Paul Tudor Jones 50,000 sh (+198.61%)
RS Investment Management 470,800 sh (-7.76%)
» More
Q2 2014

ECYT Guru Trades in Q2 2014

Jim Simons 210,200 sh (New)
RS Investment Management Sold Out
Paul Tudor Jones 37,400 sh (-25.2%)
» More
Q3 2014

ECYT Guru Trades in Q3 2014

Joel Greenblatt 17,450 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 111,700 sh (-46.86%)
» More
» Details

Insider Trades

Latest Guru Trades with ECYT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-09-30 New Buy$5.96 - $9.09 $ 6.24-9%17450
George Soros 2012-06-30 Sold Out 0.07%$3.8 - $8.35 $ 6.24-6%0
George Soros 2012-03-31 Add 53.85%0.03%$3.36 - $5.89 $ 6.2468%1000000
George Soros 2011-12-31 Add 766.67%0.1%$3.06 - $11.3 $ 6.24-30%650000
George Soros 2011-09-30 New Buy0.01%$9.36 - $14.65 $ 6.24-47%75000
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.70
ECYT's P/E(ttm) is ranked higher than
95% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ECYT: 29.70 )
ECYT' s 10-Year P/E(ttm) Range
Min: 23.07   Max: 40.86
Current: 29.7

23.07
40.86
P/B 1.23
ECYT's P/B is ranked higher than
96% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. ECYT: 1.23 )
ECYT' s 10-Year P/B Range
Min: 0.97   Max: 11.64
Current: 1.23

0.97
11.64
P/S 2.85
ECYT's P/S is ranked higher than
93% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 28.14 vs. ECYT: 2.85 )
ECYT' s 10-Year P/S Range
Min: 2.43   Max: 1100
Current: 2.85

2.43
1100
EV-to-EBIT 12.85
ECYT's EV-to-EBIT is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ECYT: 12.85 )
ECYT' s 10-Year EV-to-EBIT Range
Min: -51   Max: 22.2
Current: 12.85

-51
22.2
Current Ratio 14.38
ECYT's Current Ratio is ranked higher than
92% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. ECYT: 14.38 )
ECYT' s 10-Year Current Ratio Range
Min: 1.26   Max: 25.59
Current: 14.38

1.26
25.59
Quick Ratio 14.38
ECYT's Quick Ratio is ranked higher than
92% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. ECYT: 14.38 )
ECYT' s 10-Year Quick Ratio Range
Min: 1.26   Max: 25.59
Current: 14.38

1.26
25.59

Valuation & Return

vs
industry
vs
history
Price/Net Cash 2.19
ECYT's Price/Net Cash is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. ECYT: 2.19 )
ECYT' s 10-Year Price/Net Cash Range
Min: 1.22   Max: 32.02
Current: 2.19

1.22
32.02
Price/Net Current Asset Value 2.13
ECYT's Price/Net Current Asset Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. ECYT: 2.13 )
ECYT' s 10-Year Price/Net Current Asset Value Range
Min: 1.22   Max: 21.88
Current: 2.13

1.22
21.88
Price/Tangible Book 1.23
ECYT's Price/Tangible Book is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. ECYT: 1.23 )
ECYT' s 10-Year Price/Tangible Book Range
Min: 1.19   Max: 9.84
Current: 1.23

1.19
9.84
Price/Median PS Value 0.30
ECYT's Price/Median PS Value is ranked higher than
97% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 2.20 vs. ECYT: 0.30 )
ECYT' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 49.8
Current: 0.3

0.27
49.8
Price/Graham Number 1.15
ECYT's Price/Graham Number is ranked higher than
98% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. ECYT: 1.15 )
ECYT' s 10-Year Price/Graham Number Range
Min: 1.08   Max: 1.12
Current: 1.15

1.08
1.12
Earnings Yield (Greenblatt) 7.80
ECYT's Earnings Yield (Greenblatt) is ranked higher than
97% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. ECYT: 7.80 )
ECYT' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 684.3
Current: 7.8

4.5
684.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:9EY.Germany,
Endocyte, Inc. was incorporated in the State of Indiana in 1995 and was reincorporated in the State of Delaware in 2001. It is a biopharmaceutical company developing targeted therapies for the treatment of cancer and inflammatory diseases. It uses its proprietary technology to create novel small molecule drug conjugates, or SMDCs, and companion imaging agents. The Company is also developing companion imaging agents for each of its SMDCs that are designed to identify the patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. Its SMDC candidate, vintafolide, targets the folate receptor, which is frequently over-expressed on cancer cells. The biotechnology and pharmaceutical industries are highly competitive. Currently, it owns 11 issued U.S. patents in whole. Government authorities in the United States (including federal, state and local authorities) and in other countries regulate, among other things, the manufacturing, research and clinical development, marketing, labeling and packaging, distribution, post-approval monitoring and reporting, advertising and promotion, and export and import of pharmaceutical products.
» More Articles for ECYT

Headlines

Articles On GuruFocus.com
comment on ECYT Mar 06 2013 
Merck: Ready to Rise on New Drugs Apr 18 2012 
3.13 Jan 30 2012 
Lots of insider trad Jan 13 2012 

More From Other Websites
Others Overlooked Endocyte (ECYT), Should You Buy It Now? Dec 08 2014
Why Endocyte (ECYT) Could Be Positioned for a Surge? Nov 28 2014
Can Endocyte (ECYT) Keep the Earnings Streak Alive This Quarter? Nov 20 2014
ENDOCYTE INC Financials Nov 15 2014
ENDOCYTE INC Files SEC form 10-Q, Quarterly Report Nov 07 2014
Endocyte, Inc. (ECYT) in Focus: Stock Surges 18% Nov 07 2014
Endocyte beats 3Q profit forecasts Nov 05 2014
Endocyte beats 3Q profit forecasts Nov 05 2014
Endocyte Reports Third Quarter Financial Results and Provides Clinical Update Nov 05 2014
ENDOCYTE INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Nov 05 2014
Endocyte Reports Third Quarter Financial Results and Provides Clinical Update Nov 05 2014
Q3 2014 Endocyte Inc Earnings Release - After Market Close Nov 05 2014
Endocyte to Present at the 2014 Credit Suisse Healthcare Conference Nov 04 2014
Will Endocyte (ECYT) Miss This Earnings Season? Nov 04 2014
Endocyte Announces Third Quarter 2014 Earnings Conference Call Oct 29 2014
Endocyte Announces Third Quarter 2014 Earnings Conference Call Oct 29 2014
ENDOCYTE INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Oct 01 2014
Why Endocyte (ECYT) Stock Is Declining Today Sep 30 2014
Endocyte downgraded by Brean Capital Sep 30 2014
Endocyte's TARGET Interim Data Positive for Lung Cancer Sep 29 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK